Description
Tydol (Tapentadol) 100 mg
Tydol 100 mg is identified as a tapentadol-containing oral analgesic. Tapentadol is an opioid pain medicine used for moderate to severe pain. Regulatory sources for tapentadol tablets describe it as a controlled prescription opioid with important safety restrictions.
Active Ingredient and Medicine Class
The verified active ingredient is tapentadol. It is a centrally acting analgesic with µ-opioid receptor agonist activity and noradrenaline reuptake inhibition, a dual mechanism that places it among MOR-NRI analgesics.
Established Medical Uses
Tapentadol tablets are indicated for the management of acute pain severe enough to require an opioid analgesic and, in some regulatory settings and formulations, for chronic severe pain. Clinical studies have also evaluated tapentadol immediate-release in moderate-to-severe acute postoperative and musculoskeletal pain.
How It Works
Tapentadol relieves pain by acting in two ways: it activates opioid receptors in the central nervous system and also reduces noradrenaline reuptake. Together, these actions decrease pain signalling and help explain its analgesic effect.
Important Safety Information
Tapentadol is contraindicated in patients with significant respiratory depression, acute or severe bronchial asthma in unmonitored settings, known or suspected gastrointestinal obstruction including paralytic ileus, and hypersensitivity to tapentadol or any product ingredient. It also carries class opioid risks including addiction, abuse, misuse, and potentially life-threatening respiratory depression.
Important interaction concerns include other central nervous system depressants such as benzodiazepines, sedatives, other opioids, alcohol, and serotonergic medicines, which may increase harm. Mixed agonist/antagonist and partial agonist opioids may reduce its analgesic effect or precipitate withdrawal.
Possible Side Effects
Common adverse effects reported for tapentadol tablets include dizziness, somnolence, nausea, vomiting, constipation, pruritus, and sweating. More serious reactions can include severe sedation, breathing problems, serotonin syndrome, seizures, and severe allergic reactions.
Scientific Evidence
Peer-reviewed reviews and clinical summaries support tapentadol as an effective analgesic for moderate to severe pain, with a dual mechanism that may offer a different tolerability profile from some traditional opioids. Published evidence suggests gastrointestinal adverse effects may be less frequent than with oxycodone in comparative studies, although opioid-class risks remain.
Medical Information Notice
This educational summary is based on sources available at the time of review and does not replace the official patient leaflet, prescribing information, or individual assessment by a qualified healthcare professional.
Medical Sources
- U.S. Food and Drug Administration / DailyMed: Tapentadol tablets for oral use, prescribing information. Link
- U.S. Food and Drug Administration: NUCYNTA (tapentadol) tablets for oral use, prescribing information. Link
- Schrew, et al. “The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol.” Current Opinion in Supportive and Palliative Care, 2014. PubMed
